This analytic model assessed the per-woman cost differences between the use of 2 levonorgestrel-releasing intrauterine devices, from a US payer perspective.
Melissa Lingohr-Smith, PhD
Advertisement
Articles by Melissa Lingohr-Smith, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
FDA Approves Sacituzumab Govitecan for First-Line Treatment of Advanced Triple-Negative Breast Cancer
3
Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia
4
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Advanced NSCLC
5